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Dengue virus infection is a very deadly disease that threatens human lives in subtropical and tropical regions. Thus, for early and
reliable diagnosis of Dengue virus infection, a sensitive, specific, and label-free electrochemical immunosensor was developed
for the direct detection of the unstructured protein NS1. The NS1 biosensor was designed with a biosensing surface consisting
of antifouling moieties and biorecognition molecules to enhance the specificity of the immunosensor for target analyte detection
in complicated biological samples such as human sera. The immunosensor exhibited a wide detection range (5–4000 ng mL−1)
based on electrochemical impedance spectroscopy (EIS) measurements with a coefficient of determination (R2) of 0.94, correlation
coefficient (R) of 0.95, high reproducibility, and good stability for 21 days at 4◦
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Because of the absence of an efficient treatment or vaccine for
Dengue fever, a suitable diagnostic technique is necessary to detect
the disease consistently and rapidly.1 There are several types of diag-
nostic tests for the detection of the Dengue virus (DENV). Traditional
diagnostic techniques for DENV include isolation in cell culture,2
serological testing,3 and polymerase chain reaction (PCR).4,5 How-
ever, virus isolation is only effective if the sera samples are collected
before the onset of fever.2,6 Real time PCR (RT-PCR) often yields
false-negative results.5,7,8 Serological tests for DENV detection are
not generally specific because the immunoglobulins for DENV are
highly cross-reactive with other flavivirus antibodies (e.g., Japanese
encephalitis virus and Powassan/Deer tick virus).9 Compared with
conventional tests for the detection of DENV, biosensors, and espe-
cially electrochemical immunosensors, have received increased atten-
tion because of their sensitivity, simplicity, and specificity.10
More recently, for Dengue disease diagnostics, the detection of the
NS1 antigen biomarker has been considered because the NS1 antigen
is secreted during the early phase of DENV infection with a con-
centration of up to 50 μg mL−1,11,12 even when viral RNA detection
is negative.13 Moreover, NS1 is measurable in sera of patients with
Dengue from day 1 to day 18 after the onset of fever in both primary
and secondary infections and in the Dengue hemorrhagic fever (DHF)
stage.13,14 This indicates that NS1 is suitable for early diagnosis and
can be detected before Dengue antibodies (IgM and IgG) are present
in patient sera.14,15 Moreover, NS1 is a promising alternative for the
serum glycoprotein13 as it is stable, highly conserved, specific for
DENV infection, and non-reactive with other viruses such as the West
Nile, yellow fever,16,17 and Japanese encephalitis viruses.18 Because
of these advantages of NS1 as a DENV biomarker, it was selected for
use in this study.
Several electrochemical immunosensors have been reported for
NS1 antigen detection. Silva and co-workers described an im-
munosensor that was fabricated on the basis of the immobilization
of anti-NS1 antibodies onto an electrode surface by using a thin layer
of poly(allylamine) assembled on carboxylated carbon nanotubes
(CNTs).19 The detection of NS1 by using this reported immunosensor
was based on the electrochemical response to the immunoreaction,
which was generated at a controlled potential by a reaction between
hydrogen peroxide and peroxidase enzyme conjugated to anti-NS1
antibodies. The limit of detection for this immunosensor was 0.035
μg mL−1, which is slightly lower than NS1 levels in sera of patients
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with primary infections (range of NS1 levels is 0.04–2 μg mL−1) and
higher than NS1 levels in sera of patients with secondary infections
(range of NS1 levels is 0.01–2 μg mL−1).13 Another reported im-
munosensor for NS1 detection was fabricated based on CNT-screen
printed electrodes (CNT-SPE).20 This immunosensor exhibited a low
detection limit of 12 ng mL−1. Evaluation of NS1 concentration was
based on the measurement of amperometric responses by using hydro-
gen peroxide reaction with peroxidase (HRP) conjugated to anti-NS1
antibodies. In the above mentioned studies, labeling techniques were
used for the electrochemical biosensors to improve inadequate sensi-
tivity results. However, the labeling process might induce structural
changes to the labeled macromolecules.19 Moreover, these techniques
are costly and require increased sample preparation time and tedious
detection procedures.19 The operation of these immunosensors essen-
tially depends on the detection of hydrogen peroxide. However, all
biological samples contain a variety of electrochemically easily oxi-
dizable reductants such as ascorbate and bilirubins. These reductants
tend to be oxidized at similar potentials and generate undesired noise,
which, in addition to the anodic current produced by the hydrogen
peroxide, could reduce the sensitivity of biosensors.21
As a model of a label-free immunosensor, a thiophene-modified
screen printed electrode (SPE) as reported by Saliva et al.22 was devel-
oped for the detection of NS1 antigen. The incorporation of thiophene
monomers with carbon ink enhanced the electroanalytical properties
of the SPEs and increased their reproducibility and sensitivity (detec-
tion limit of 0.015 μg mL−1 NS1). However, analytical performance
studies of these immunosensors were conducted without examining
selectivity or cross-reactivity, thus providing insufficient information
about the specificity of these immunosensors for the specific detection
of the NS1 antigen. Another label-free immunosensor was fabricated
on the basis of gold film electrodes that were obtained from a record-
able compact disk (CD-trode).23 This immunosensor exhibited a linear
response from 1 to 100 ng mL−1 of NS1 detection in serum samples.
However, the selectivity study for this immunosensor was conducted
against bovine serum albumin, l-cysteine, and IgG of unknown origin.
Using these molecules might not be representative of biomolecules
typically found in human sera, as noted by Cavalcanti et al.23 and in
other reports of immunosensors developed for NS1 detection.19,20,22
Even though most of the above mentioned techniques have shown rea-
sonably good limit of detection and high sensitive sensoring interface
for NS1 biomarker detection, however apart from the research work
reported by Cecchetto et al.1 and the studies conducted as described
in this manuscript, most of the analytical responses and the calibra-
tion curves generated for other presented biosensors were obtained
either in phosphate buffer saline19,20,23 or in Dengue virus culture
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supernatant.22 Therefore the ability of a biosensor to sense the NS1
biomarker in human sera samples is challenging but extremely impor-
tant. This is not only to show the biosensor could really work well in
real sample analysis for biomedical applications/clinical diagnostics
and potentially to be prototyped and commercialized, but also to show
the novelty and robustness of the biosensing interface being able to
resist any non-specific absorption of proteins from the complex ma-
trices onto the transducer surfaces and give false negative responses
where the accuracy and precision of data obtained are being compro-
mised. Therefore, the aim of this study was to develop a label-free,
straight-forward, specific, and sensitive immunosensor utilizing zwit-
terionic antifouling molecules and based on nanoparticle-customized
electrochemical techniques and monoclonal antibodies for the direct
detection of NS1 antigens in blood specimens infected with DENV.
Experimental
Reagents and materials.—ITO was purchased from Sanyo
(Japan). The following were purchased from Sigma-Aldrich (USA):
4-sulfophenyl, 1,4-phenylenediamine, sodium nitrite (NaNO2), potas-
sium chloride (KCl), potassium dihydrogen phosphate (KH2PO4),
potassium phosphate dibasic (K2HPO4), hydrochloric acid (HCl),
potassium ferricyanide (K3Fe(CN)6), gold nanoparticles (AuNPs) (20
nm), human serum albumin (HSA), and sodium chloride (NaCl). Hu-
man IgG was obtained from Thermo Fisher Scientific (USA) and
4-trimethylammoniophenyl was obtained from Acros (USA). The
NS1 antigen and monoclonal anti-NS1 IgG antibody were purchased
from GenScript (USA). ELISA-based serological assays and Dengue
NS1 Ag + Ab Combo tests (Standard diagnostics, Korea). All solu-
tions were prepared using Milli-Q water (18 M•cm−1) (PURELAB,
USA).
Instrumentation and procedures.—All electrochemical measure-
ments were performed using an AutoLabIII potentiostat (Metrohm
AutoLab, Netherlands) and a conventional three-electrode system
consisting of an ITO working electrode, a platinum wire as the aux-
iliary electrode, and Ag/AgCl (3.0 M NaCl) as the reference elec-
trode. All potentials were reported relative to the Ag/AgCl refer-
ence electrode at 25◦C. The surface studies on the modified sensing
interface were performed in an aqueous solution containing redox
probes [Fe(CN)6]4−/3− (1 mM) composed of 0.05 M KCl, 0.05 M
K2HPO4, and 0.05 M KH2PO4 adjusted to pH 7.0. Electrochemi-
cal impedance spectroscopy (EIS) techniques and differential pulse
voltammetry (DPV) were used to probe the integrity of functionalized
layers on electrode surfaces and to obtain the calibration curve for the
NS1 antigen. The electrodeposition of different layers onto the ITO
electrode surface was performed using cyclic voltammetry at −0.6 V
to 0.2 V at 100 mV s−1. The EIS measurements were performed
within the frequency range of 0.1–103 Hz and 10 points per decade
of frequencies with a single sine wave type at 25◦C. Nova software
(Metrohm AutoLab, Netherlands) was used to model the complex cir-
cuit. The following parameters were used for the DPV measurements:
initial potential (−0.2 V), end potential (0.6 V), modulation ampli-
tude (25 mV), modulation time (0.05 s), interval time (0.5 s), and step
potential (5 mV).
Fabrication of a label-free electrochemical impedance im-
munosensor for direct detection of the NS1 antigen.—ITO substrates
were soaked and cleaned in an ultrasonicator using dichloromethane
and then 99% methanol for 10 min each, followed by treatment
with 0.5 M K2CO3 in a 3:1 methanol:Milli-Q water mixture for
30 min under sonication to remove any residual organic contami-
nants. The ITO substrates were then rinsed with copious amounts
of Milli-Q water, dried, and stored in a nitrogen-filled container.24
The bare ITO electrode was modified with a combination of 4-
sulfophenyl, 4-trimethylammoniophenyl, and 1,4-phenylenediamine
(SP:TMAP:PPD) at molar ratio of 0.5:1.5:0.37. This ratio was selected
as it exhibited the best antifouling capabilities against positively and
negatively charged proteins.25 For modification of the electrode sur-
face, an in situ method was used in which aryl diazonium cations
were electrochemically reduced with two times the molar amount of
NaNO2 in 0.05 M HCl. The modification solution was purged with
nitrogen gas for 20 min before the surface modification. The elec-
trodeposition was performed using cyclic voltammetry at −0.6 V to
0.2 V; the electrodes were scanned for 5 cycles at 100 mV s−1 to pro-
duce the first layer on the ITO electrode.26,27 This surface is referred to
as surface 1 (Scheme 1). Subsequently, the distal amine groups of 1,4-
phenylenediamine were converted to diazonium groups by incubating
surface 1 in NaNO2 and 0.5 M HCl solution to produce a 4-phenyl dia-
zonium chloride-modified interface (ITO-Ph-N2+Cl−). Subsequently,
AuNPs were immobilized on the interface by electrochemical reduc-
tion to give a 4-phenyl AuNP-modified interface (ITO-Ph-AuNP).
The diazonium radicals link to the AuNPs via a covalent bond.27 The
ITO electrodes were first modified with 4-aminophenyl in mixture
of SP:TMAP:PPD, and then the terminal amine of 4-aminophenyl
was converted to diazonium groups by incubating the modified in-
terface in NaNO2 and HCl solution to form a 4-phenyl diazonium
chloride-modified interface (ITO-Ph-N2+Cl−). Subsequently, AuNPs
were immobilized on the interface by electrochemical reduction to
give a 4-phenyl AuNP-modified interface (ITO-Ph-AuNP). The dia-
zonium radicals link to the AuNPs via a covalent bond,27 and this is
referred to as surface 2 (Scheme 1). Note that AuNPs are used as they
yield an enlargement of the electrode surface area, boost the interface
with more bio-recognition molecules (as they have a high surface-to-
volume ratio), exhibit advantageous redox properties, and are capable
of sensing analytes in the pM range.28–30 Next, 1,4-phenylenediamine
(3 mM) was used to functionalize AuNPs on surface 2, allowing for the
subsequent attachment of monoclonal anti-NS1 IgG antibodies onto
the AuNPs. The AuNPs were modified with 1,4-phenylenediamine by
using a scanning potential between 0.2 V and −0.6 V in a 0.5 M HCl
solution containing 1 mM NaNO2 and 3 mM 1,4-phenylenediamine
for three cycles at a scan rate of 100 mV s−1. This surface is referred
to as surface 3 (Scheme 1). Monoclonal anti-NS1 IgG antibodies
were incubated with 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide
(EDC) (200 mM) and N-hydroxysulfosuccinimide (NHS) (50 mM)
cross linkers for 30 min to activate carboxyl groups of the monoclonal
antibodies.31 Then, 50 μL of this solution was added to surface 3
and incubated for 45 min at 25◦C to bind the monoclonal antibodies
to the amine groups of 1,4-phenylenediamine. After, the ITO slides
were washed with 50 mM NaCl to remove any extra unbound anti-
bodies on the electrode surface, and then they were washed with 10
mM phosphate buffer solution (PBS) at pH 7.4. This surface is re-
ferred to as surface 4. Surface 4 is the sensing interface that was used
for the detection of the NS1 antigen. The NS1 antigen was spiked
into diluted human sera (10% in PBS, pH 7.4) at various concentra-
tions. The NS1 antigen (50 μL) was pipetted onto surface 4, and the
slides were incubated for 45 min at 25◦C. Then, the immunosensors
were rinsed thoroughly with PBS (pH 7.4) prior to DPV and EIS
measurements.
Analysis of reproducibility, stability, selectivity, and cross-
reactivity of the NS1 immunosensor.—The reproducibility of the
fabricated immunosensor was examined by testing five different mod-
ified electrodes as mentioned earlier. Then, the prepared slides were
incubated in a NS1 antigen solution (100 ng mL−1) for 45 min. Af-
ter, the slides were soaked in PBS (pH 7.4) for 5 min and washed
carefully with PBS (pH 7.4) to remove any nonspecifically adsorbed
NS1 antigen. The peak current of DPV was measured for each slide,
and the relative standard deviation for the five slides was calculated.
For the stability study, eighteen slides were modified as described
earlier. Then, three of these slides were tested on the same day. The
NS1 immunosensor was incubated in 50 μL of NS1 antigen (100 ng
mL−1) for 45 min. The other fifteen slides were stored in 10 mM PBS
(pH 7.4) at 4◦C. Thereafter, three slides were tested each day at days
7, 14, 21, 30, and 60 to determine the stability of the modified ITO
over a 60-day period. Prior to each test, the NS1 immunosensor was
rinsed with 10 mM PBS (pH 7.4). The peak current values were mea-
sured for each slide by using DPV, and the relative standard deviation
Scheme 1. Schematic of fabrication of an electrochemical immunosensor for direct detection of the biomarker NS1 antigen during early stages of Dengue virus
infection.
was calculated. For the selectivity study, twelve modified slides were
used. Three of these slides were incubated with 50 μL of NS1 antigen
(50 ng mL−1). Another three of the modified slides were incubated
with 50 μL of HSA (50 ng mL−1) from normal human sera. The last
three modified slides were incubated with 50 μL of human IgG (50 ng
mL−1). After incubation for 45 min, the slides were electrochemically
measured using EIS. Then, charge transfer resistance (Rct) values of
slides incubated with NS1 antigen were compared to Rct values of
slides incubated with HSA and human IgG. For the cross-reactivity
study, six modified slides were used. Three of these slides were incu-
bated with 50 μL of 10% human sera diluted with PBS (pH 7.4) and
spiked with NS1 antigen (1 μg mL−1). Another three of the prepared
slides were incubated with 50 μL of 10% human sera diluted with
PBS (pH 7.4) taken from a patient infected with the malaria parasite.
After incubation for 45 min, the slides were electrochemically mea-
sured using EIS. Rct values of slides incubated with the NS1 antigen
were compared to Rct values of slides incubated with the infected sera
with malaria parasites.
The potential use of the fabricated immunosensor in clinical di-
agnostics was further tested by using five actual sera samples from
patients infected with DENV. Beforehand, these samples were tested
and confirmed positive for NS1 and negative for IgM and IgG by
both ELISA-based serological assays and Dengue NS1 Ag + Ab
Combo tests. As control samples, five normal sera samples were col-
lected from patients with negative results for NS1, IgM, and IgG. The
positive and negative sera samples were serially diluted to various
dilution factors (1:10, 1:100, 1:500, and 1:1000) by using PBS (pH,
7.4). The modified slides were incubated with 50 μL of diluted sera
at the various dilutions. After incubation for 45 min, the slides were
electrochemically measured using EIS. Then, Rct values of slides in-
cubated with positive sera samples was compared to Rct values of
slides incubated with negative sera samples.
Results and Discussion
An electrochemical immunosensor for direct detection of the
NS1 antigen.—EIS was used to monitor the stepwise fabrication
of the biosensor by using 1 mM Fe(CN)63−/Fe(CN)64−. A Randles
equivalent circuit was used to fit the impedance results and contains
the following four elements: the resistance of the electrolyte solu-
tion (RS), phase constant element (Q), Warburg impedance (W), and
charge transfer resistance Rct (Table I). The RS and W elements relate
to the properties of the electrolyte solution and the diffusion features
of the redox probe, respectively. The diffusion of the redox probe
is represented on a Nyquist plot by a straight line at low frequen-
cies. The Rct and Q elements represent the dielectric and insulating
characteristics at the electrode/electrolyte interface, and therefore,
the values of these two elements are affected by the modification
of the electrode surface. They are represented by the semicircle of
the Nyquist plot. The semicircle diameter is typically proportional
to the resistance of the deposited layers on the electrode surface.
Forming a well-organized layer on the modified electrode generally
hinders the diffusion of the redox probe, since an increase in the di-
ameter of the semicircle causes a high electron transfer resistance. A
substantial change in the diameter of the semicircle on the Nyquist
plot, and therefore Rct, was detected during the fabrication steps of
the NS1 immunosensor (Figure 1a and Table I). After the modifi-
cation of ITO with 4-sulfophenyl, 4-trimethylammoniophenyl, and
1,4-phenylenediamine molecules to produce surface 1 (Scheme 1), an
increase in the Rct was observed as this organic layer prevented the
redox molecule from accessing the electrode (Figure 1aII and Table I).
However, when AuNPs were attached, there was a significant decrease
in the Rct (Figure 1aIII and Table I), and this observation is consistent
with other studies showing that AuNPs can decrease the resistance
of charge transfer when they are attached to blocking layers.32,33 The
Table I. Values of equivalent circuit parameters of the fitting curve for the bottom-up stepwise fabrication of the NS1 electrochemical impedance
immunosensor interface by Nova software.
Electrodesa Rs () Rct () CPE N χ2
Bare ITO 393.9.0 ± 5.4 279.3 ± 64.1 65701 × 10−6 ± 1.01 × 10−6 0.9 ± 3 × 10−2 0.007 ± 7 × 10−3
ITO/SP:TMAP:PPD 34.0 ± 1.0 10072.2 ± 3075 6.4 × 10−6 ± 4.1 × 10−6 0.9 ± 9 × 10−3 0.01 ± 6 × 10−3
ITO/ SP:TMAP:PPD /GNPs 39.6 ± 9.5 2012.1 ± 1174 77 × 10−6 ± 1.3 × 10−6 0.9 ± 2 × 10−2 0.03 ± 2 × 10−3
ITO/ SP:TMAP:PPD /GNPs/PPD 30.3 ± 2.5 6537.4 ± 2555 7.5 × 10−6 ± 1.8 × 10−6 0.9 ± 1 × 10−2 0.01 ± 8 × 10−3
ITO/SP:TMAP:PPD/GNPs/PPD/Monoclonal 27.7 ± 1.7 7510.2 ± 1716 6 × 10−6 ± 0.76 × 10−6 0.9 ± 1 × 10−2 0.004 ± 2 × 10−3
anti-NS1 IgG antibody
aValues correspond to the average of three separate measurements ± standard deviation.
Rs, the resistance of the electrolyte solution.
Rct, charge transfer resistance.
CPE, constant phase element.
An n-value for CPE near 1.0 indicates a true capacitance.
X2, estimated error.
deposition of 1,4-phenylenediamine caused an increase in the Rct (Fig-
ure 1aIV and Table I), and further increases in the Rct were detected
when monoclonal anti-NS1 IgG antibodies were covalently bound to
1,4-phenylenediamine by using EDC/NHS (Figure 1aV and Table I).
Moreover, an increase in the Rct was observed when the NS1 antigen
bound specifically to the monoclonal anti-NS1 IgG antibody layer.
In addition, electrochemical characterization of the fabricated NS1
immunosensor was performed using DPV to support our EIS results
(supplementary information, Figure S1.a).
Quantitative analysis of the NS1 antigen biomarker in human
sera.—A calibration curve was obtained using the NS1 immunosensor
functionalized with monoclonal anti-NS1 IgG antibodies to detect the
NS1 antigen at various concentrations in 10% human sera diluted with
PBS (pH 7.4). The calibration curve obtained from a Nyquist plot of
the impedance spectra showed a logarithmic relationship (log-linear
model) between the Rct measurements and various concentrations of
the NS1 antigen being spiked into the diluted samples of human sera
(Figure 1b). The coefficient of determination (R2) obtained was 0.94
for the dynamic range ranged from 5 to 4000 ng mL−1. On the other
hand, the correlation coefficient (R) calculated was 0.95 and this value
indicates the strong relationship found between the Rct measurements
and NS1 concentrations detected in human sera samples (Figure 1b).
For statistical analysis purpose, a residual plot has been generated
to assess the regression and relation between the Rct measurements
and NS1 protein concentrations. Figure S2 (Supplementary material)
shows all the points obtained in this residual plot were randomly
dispersed around the horizontal axis which again has double confirmed
the linear regression model for Rct and NS1 variables (5–4000 ng
mL−1) with P value of 0.4. The ability of the developed immunosensor
to detect the NS1 antigen in serum samples with a detection limit of 5
ng mL−1 is acceptable for clinical applications, since NS1 levels range
from 0.04 to 2 μg mL−1 in primary infection sera and from 0.01 to
2 μg mL−1 in secondary infection sera.13 In addition, to support our
findings obtained from the EIS measurements, DPV methods were
used to determine the relationship between the concentration of the
NS1 antigen and the peak current of DPV (Supplementary material,
Figure S1.b).
The ability of the NS1 immunosensor to approach such a low de-
tection limit might result from the use of antifouling molecules. In
our previous work,25 it was shown that these antifouling molecules
with charged terminal groups can counter the non-specific adsorp-
tion of the various proteins naturally found in human sera. Other
reported immunosensors using AuNPs modified with polyvinyl bu-
tyral (PVB),30 concanavalin A,34 polyaniline hybrid,35 or Fe3O4
nanoparticles36 served as models for the detection of DENV. In these
biosensors, lectins (proteins or glycoproteins from different sources)
were immobilized on the biosensor surface to detect glycoproteins
and the immune response produced in patients infected by DENV.
Lectins are carbohydrate-binding proteins; therefore, they are able to
bind to serum glycoproteins.35,36 The majority of serum proteins are
glycosylated when there is an infection, and glycoproteins will be
changed to abnormal glycoproteins under conditions such as liver
disease, cancer, or Dengue fever. These changes could provide a
basis for clinical tests.37 Unfortunately, the presence of these gly-
coproteins could be because of DENV infection or other diseases.
Figure 1. (a) Nyquist plots recorded in PBS containing 0.05 M KCl and 1 mM Fe(CN)63−/Fe(CN)64− for impedance measurements of the stepwise
surface modification of (i) bare ITO electrode, (ii) ITO/SP:TMAP:PPD, (iii) ITO/SP:TMAP:PPD/GNPs, (iv) ITO/SP:TMAP:PPD/GNPs/PPD, and (v)
ITO/SP:TMAP:PPD/GNPs/PPD/NS1 monoclonal IgG antibody (50 μg mL−1). (b) The calibration plot corresponding to the increase in electron transfer re-
sistance of the immunosensor with various concentrations of NS1 antigen (5, 10, 20, 100, 1000, 2000, 3000, and 4000 ng mL−1). Note: (a) inset is the Randles
equivalent circuit for the impedance spectroscopy measurement.
Figure 2. (a) The reproducibility study based on the peak height of DPV measurement for five different electrodes incubated in NS1 antigen solution (100 ng
mL−1) (the relative standard deviation obtained was 2.1%). (b) The changes of impedance observed in the selectivity study where the immunosensing interfaces
were tested with 50 ng mL−1 of target NS1 antigen, human IgG, and human serum albumin, respectively. (c) The changes of impedance observed in the cross-
reactivity study where the immunosensing interfaces were incubated in samples of 10% human sera spiked with NS1 (1 μg mL−1) and 10% human sera infected
with malaria parasites, respectively. (d) The stability study where the peak height of DPV measurement was recorded and compared for electrodes tested with NS1
concentration of 100 ng mL−1 for 60 days stored at 4◦C. The error bars indicate the standard deviation of three replicates.
This indicates that these biosensors based on serum glycoproteins
might not be highly specific to DENV infection, since serum glyco-
proteins could be detected in both infected and non-infected serum
samples.35
Analytical performance of the NS1 immunosensor: Repro-
ducibility, selectivity, cross-reactivity, and stability studies.—The
reproducibility of the immunosensor was examined by testing five
different electrodes incubated with 100 ng mL−1 NS1 antigen. High
reproducibility was achieved with relative standard deviation (RSD =
2.1%) (Figure 2a), indicating that the electrochemical measurements
were more stable than those of previous immunosensors,20,23 which
had a reproducibility of RSD = 3.4% and RSD = 4.8%. Reproducibil-
ity is one of the most important challenges limiting the commercial-
ization of any biosensor. The high reproducibility of the fabricated
NS1 immunosensor might be attributable to the biosensor design and
fabrication procedure.38 Using a monoclonal antibody for the specific
detection of the NS1 antigen could enhance the reproducibility of the
immunosensor.39 In addition, using antifouling molecules can control/
resist the non-specific protein adsorption to the immunosensing inter-
face. Consequently, the obtained current peak measurements were
stable and proportional to the concentration of only the NS1 antigen.
Furthermore, the reproducibility and the robustness of the fabricated
immunosensor might indicate that the monoclonal anti-NS1 antibod-
ies were uniformly distributed on the electrode matrix.40 To investigate
the selectivity/specificity of the developed NS1 immunosensor to the
NS1 antigen, human IgG and HSA were tested to determine whether
the NS1 immunosensor yields any positive response signals to these
molecules in the absence of the NS1 antigen. An additional objective
of this study was to rule out any possibility of human IgG and HSA
inducing a biofouling effect and compromising the accuracy and re-
liability of the obtained analytical signal. Human IgG and HSA were
tested as controls as they are major blood proteins found in human
sera and will be the main components competing with the NS1 antigen
or causing biofouling of the biosensor interface. Figure 2b shows that
the NS1 immunosensor did not significantly respond to HSA and hu-
man IgG. In contrast, the NS1 immunosensor showed a much greater
response and an increased Rct value only in response to the NS1
antigen. This result indicates that the NS1 immunosensor has a high
specificity for the detection of only the NS1 antigen, and any response
obtained corresponded to the NS1 antigen. Furthermore, the fabricated
antifouling surface exhibited high resistance to the biofouling effect,
which might be attributable to the non-specific protein adsorption of
human IgG and HSA (Figure 2b). Using antifouling moieties (zwitte-
rionic molecules) in the fabricated immunosensor might enhance its
selectivity as this aided in overcoming the issue of protein fouling,
which is the non-targeted molecular binding to the sensor interface,
particularly when detecting biomarkers in biological samples such as
human sera.
In some diagnostic methods that have been used to detect DENV
infection, including the hemagglutination-inhibition (HAI) assay
and the MAC-ELISA-IgM assay, false-positive readings have been
reported.41 These results have been ascribed mainly to cross-reactivity
with co-circulating antibodies from either other flaviviruses such as
the Japanese encephalitis virus or those that can be found in sera
of patients with leptospirosis or chikungunya.7,42 Cross-reactivity in
patients with DENV infection who also test positive for malaria is
a well-known issue in regions such as West Africa. Nevertheless,
the relationship between these two diseases is not well defined. The
cross-reactivity is considered an obstacle to commercially available
serology kits and rapid diagnostic tests used for clinical diagnosis.43,44
Therefore, in this study, an assessment of cross-reactivity was also
conducted to determine if the sera taken from patients infected
with malaria parasites displayed a positive response for NS1 antigen
Figure 3. Response to the NS1 antigen in positive
and negative human sera at different dilution fac-
tors (1:10, 1:100, 1:500, and 1:1000) from a patient
infected with the Dengue virus.
detection. The NS1 immunosensor did not exhibit a significant re-
sponse to malaria-infected sera (Figure 2c), but showed a much greater
response to NS1 antigen. Selectivity is the most important characteris-
tic of a biosensor and is another potential advantage of the immunosen-
sor fabricated in this study compared with other reported biosensors
that were not evaluated for sensor selectivity.19,20,22 In research done
by Cavalcanti et al.,23 the selectivity study was carried out against
bovine serum albumin, l-cysteine, and IgG of unknown origin. How-
ever, these might not represent biomolecules normally found in human
sera. The high selectivity of the immunosensor fabricated in this study
might be attributable to the high affinity between the biorecognition
site (monoclonal Ab) and the target analyte (NS1 antigen), as the
binding between antibody and antigen is the most promising method-
ology for detecting trace quantities of a specific biomarker in complex
matrices.45
The stability of the developed NS1 immunosensor was investigated
by carrying out experiments at weekly intervals. The fabricated im-
munosensing interface retains 90.4% of its activity after being stored
for 21 days at 4◦C, indicating that the monoclonal anti-NS1 IgG an-
tibody used to modify the immunosensing interface has acceptable
storage stability (Figure 2d). However, after 30 days, there was a re-
duction to 71.4% of the initial peak current (day 1). This decrease in
peak current was expected, as the typical shelf life for antibodies is 30
days, and chemical modifications such as oxidation and proteolytic
degradation can occur if these antibodies are stored for more than 30
days at 4◦C.46,47 The stability of a stock antibody can be prolonged
to one year if they are stored at −20◦C or to more than one year if
they are stored at −80◦C.47 The operational and storage properties
of the prepared NS1 immunosensor might be attributable to the fab-
rication procedure because using EDC and NHS could tightly bind
the antibody to the amine group of 1,4-phenylenediamine attached
on the AuNP surface through an amide bond, greatly improving the
stability of the modified electrode.31 In addition, the electrochemical
deposition of the AuNPs was an effective method to obtain a film
of AuNPs on the electrode. The AuNP film was distributed homo-
geneously and could tightly bind to the electrode, giving a powerful
and stable immunosensing interface.27,39 The fabrication design was
further advantageous by maintaining immunosensor stability, which
is essential for practical applications.
The developed NS1 immunosensor exhibited promising analytical
performance for clinical diagnosis because it can be used directly to
detect the NS1 protein in a single step in sera samples of patients in-
fected with DENV. There was a noticeable decrease in the Rct value for
positive sera samples, and this decrease was proportional to the dilu-
tion factor (Figure 3). However, no significant change in Rct value was
detected for negative sera samples at different dilutions. The change
in Rct value might be ascribed to the change in NS1 antigen concentra-
tion in the tested samples. The proposed immunosensor demonstrated
selectivity for DENV NS1 protein detection with satisfactory differ-
entiation from the negative sera.
Conclusions
An electrochemical immunosensor for the specific and direct
detection of the NS1 antigen was successfully developed. An im-
munosensor surface consisting of antifouling molecules and mon-
oclonal anti-NS1 IgG antibodies was fabricated based on in situ-
generated aryl diazonium cations. The dynamic range for NS1 anti-
gen detection was 5–4000 ng mL−1, indicating high analytical perfor-
mance, with coefficients of determination (R2) = 0.94 and correlation
coefficient (R) = 0.95 as determined using the EIS technique. The de-
veloped NS1 immunosensor exhibited excellent reproducibility, with
a relative standard deviation of 2.1% for the response of five indepen-
dently prepared immunosensors to 100 ng mL−1 NS1 antigen. The
NS1 immunosensor showed high stability (up to 21 days with storage
at 4◦C), high selectivity to the NS1 antigen (no response to human
IgG or HSA), and no cross-reactivity with malaria-infected sera. All
of the experimental data described in this study demonstrate the po-
tential use of aryl-diazonium-cation-derived zwitterionic antifouling
molecules and monoclonal anti-NS1 IgG antibodies for the generation
of a specific ITO immunosensing interface for direct detection of the
NS1 antigen in human sera. Furthermore, this study highlights the ca-
pacity of the NS1 immunosensor as a potential clinical diagnostic test,
since the immunosensor has been shown to be capable of specifically
detecting the NS1 antigen in complex serum specimens from patients
infected with DENV.
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